TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04431765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization Reprocessing therapy
Description: The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Trauma-Centred Cognitive and Behavioural Therapy
Description: A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
Study: NCT01241110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin group A, Azitromycin group B
Description: Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azitromycin
Description: azitromicin vs ofluxacin
Study: NCT00775619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol 12.5 mg tablets fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol 12.5 mg tablets fed conditions
Study: NCT03846193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT005
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT005
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT005
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT005
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GT005/ Device: Orbit™ Subretinal Delivery System
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GT005/ Device: Orbit™ Subretinal Delivery System
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GT005/ Device: Orbit™ Subretinal Delivery System
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System
Study: NCT00104572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel (Testosterone Gel)
Description: 1 mg tablet for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Aromatase Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Daily for 12 months
Study: NCT04954963

Intervention type: DIAGNOSTIC_TEST
Intervention: Reduce metal artifacts examination
Description: patients undergo reduce metal artifacts examination
Study: NCT03285971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic CPP pager alert
Description: Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
Study: NCT04173117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy meal replacement plan (12 weeks)
Description: Low energy meal replacement plan (12 weeks)
Study: NCT04130282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313/Matrix-M1
Description: 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
Study: NCT02815865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter and pitocin
Description: Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter and Dinoprostone
Description: Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone 3 mg will be inserted to the posterior fornix
Study: NCT02973932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-bahavioral psychotherapy
Study: NCT04152720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured.
Study: NCT01017640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV
Study: NCT00104572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: Daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Cardone 500mg with vitamin D 400 IU
Description: 1 tablet three times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Cardone 500mg with vitamin D 400 IU
Description: 1 tablet three times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Cardone 500mg with vitamin D 400 IU
Description: 1 tablet three times a day
Study: NCT01017640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00005089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
Study: NCT02934464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAMUCIRUMAB
Study: NCT00795288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group
Study: NCT04451473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS )
Description: the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )
Description: the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
Study: NCT03233035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Study: NCT01181258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
Study: NCT00703092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiber-Stat
Description: Liquid fiber supplement, 2 tablespoons twice daily.
Study: NCT01181258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
Study: NCT03522831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
Study: NCT01075984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Study: NCT01510899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single dose of RO4917838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single dose of RO4917838
Study: NCT02532985

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: No added fiber beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Fiber Control
Description: positive control fiber supplemented beverage provided over 4 servings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided over 4 servings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided over 4 servings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided over 4 servings
Study: NCT03323190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient COPD education
Study: NCT01120990

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure Measurement
Description: All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
Study: NCT01577147

Intervention type: OTHER
Group type: OTHER
Intervention: Ovulation predictions products
Description: Home diagnostics for ovulation prediction will be provided to study volunteers
Study: NCT06332846

Intervention type: OTHER
Intervention: oral examination
Description: The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight

Intervention type: OTHER
Intervention: oral examination
Description: The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
Study: NCT02494427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM manufactured fixed unitary dental prostheses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally manufactured unitary dental prostheses
Study: NCT00602147

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood or cheek cells wil be collected.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood or cheek cells wil be collected.
Study: NCT04796376

Intervention type: PROCEDURE
Group type: OTHER
Intervention: combined partial fistulectomy or fistulotomy and cutting seton procedure
Description: Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
Study: NCT02258126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention program
Description: Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Description: Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months.
Study: NCT02276729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Box Therapy
Description: Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
Study: NCT03348345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Breathe Thrive
Description: Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
Study: NCT00005089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Study: NCT02004028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6063
Study: NCT02773927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in tablet presentation of 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin in tablet presentation of 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Agave inulin
Description: Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave inulin
Description: Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study: NCT04999150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-Osteoperforations
Description: MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticotomy
Description: A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)
Study: NCT03986320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeogo™ Dermoskeleton
Description: This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Study: NCT00278954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gammaplex (Intravenous immunoglobulin)
Description: GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
Study: NCT02930551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Study: NCT03410420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole hydrochloride
Description: administration of pimonidazole-HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimonidazole hydrochloride
Description: administration of pimonidazole-HCl
Study: NCT05020067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: superficial parotid lobe-sparing intensity-modulated radiotherapy
Description: The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
Study: NCT04476524

Intervention type: OTHER
Intervention: Quality improvement
Description: All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Quality improvement
Description: All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
Study: NCT00807079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT00929526

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liquid-based cytology (LBC) sampling
Description: LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) sampling
Description: LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected at Months 36 and 48 for antibody determination
Study: NCT03305705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Single intravenous infusion within 20 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Single intravenous infusion within 20 min
Study: NCT00005089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.